Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: The good, the bad, or the evil?

被引：7

作者：

Andersen, MH ^{[1
]}

Reker, S

Stratem, PT

Gehl, J

Geertsen, P

Becker, JC

机构：

[1] Danish Canc Soc, Tumor Immunol Grp, Copenhagen, Denmark

[2] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark

[3] Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 22期

关键词：

D O I：

10.1200/JCO.2004.00.9837

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5265 / 5267

页数：3

共 10 条

[1]

Andersen MH, 2001, CANCER RES, V61, P869

[2] Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration [J].

Andersen, MH ;

Gehl, J ;

Reker, S ;

Pedersen, LO ;

Becker, JC ;

Geertsen, P ;

Straten, PT .

SEMINARS IN CANCER BIOLOGY, 2003, 13 (06) :449-459

[3] MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100 IS RECOGNIZED BY MELANOMA-DERIVED TUMOR-INFILTRATING LYMPHOCYTES [J].

BAKKER, ABH ;

SCHREURS, MWJ ;

DEBOER, AJ ;

KAWAKAMI, Y ;

ROSENBERG, SA ;

ADEMA, GJ ;

FIGDOR, CG .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :1005-1009

[4] IDENTIFICATION OF THE IMMUNODOMINANT PEPTIDES OF THE MART-1 HUMAN-MELANOMA ANTIGEN RECOGNIZED BY THE MAJORITY OF HLA-A2-RESTRICTED TUMOR-INFILTRATING LYMPHOCYTES [J].

KAWAKAMI, Y ;

ELIYAHU, S ;

SAKAGUCHI, K ;

ROBBINS, PF ;

RIVOLTINI, L ;

YANNELLI, JR ;

APPELLA, E ;

ROSENBERG, SA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :347-352

[5] Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy [J].

Keilholz, U ;

Weber, J ;

Finke, JH ;

Gabrilovich, DI ;

Kast, WM ;

Disis, ML ;

Kirkwood, JM ;

Scheibenbogen, C ;

Schlom, J ;

Maino, VC ;

Lyerly, HK ;

Lee, PP ;

Storkus, W ;

Marincola, F ;

Worobec, A ;

Atkins, MB .

JOURNAL OF IMMUNOTHERAPY, 2002, 25 (02) :97-138

[6]

Letsch A, 2003, CANCER RES, V63, P5582

[7] Chemokines: multiple levels of leukocyte migration control [J].

Moser, B ;

Wolf, M ;

Walz, A ;

Loetscher, P .

TRENDS IN IMMUNOLOGY, 2004, 25 (02) :75-84

[8] Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin [J].

Otto, K ;

Andersen, MH ;

Eggert, A ;

Keikavoussi, P ;

Pedersen, LO ;

Rath, JC ;

Böck, M ;

Bröcker, EB ;

Straten, PT ;

Kämpgen, E ;

Becker, EC .

VACCINE, 2005, 23 (07) :884-889

[9] Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule [J].

Slingluff, CL ;

Petroni, GR ;

Yamshchikov, GV ;

Hibbitts, S ;

Grosh, WW ;

Chianese-Bullock, KA ;

Bissonette, EA ;

Barnd, DL ;

Deacon, DH ;

Patterson, JW ;

Parekh, J ;

Neese, PY ;

Woodson, EMH ;

Wiernasz, CJ ;

Merrill, P .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4474-4485

[10] Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes [J].

Wang, RF ;

Appella, E ;

Kawakami, Y ;

Kang, XQ ;

Rosenberg, SA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (06) :2207-2216

← 1 →